PBFT02

PBFT02 showed increased CSF PGRN levels and reduced plasma NfL levels in FTD-GRN patients. Dose 2, 50% lower than Dose 1, is being evaluated. Passage Bio extended cash runway to 1Q 2027 by reducing expenses and transitioning to outsourced analytical testing. 12-month data from Dose 1 and interim data from Dose 2 expected in 2H 2025.

Passage Bio (PASG) updated Phase 1/2 upliFT-D trial data for PBFT02 in frontotemporal dementia treatment, showing durable CSF PGRN levels and early plasma NfL reduction. Evaluating lower Dose 2 for FTD-GRN and FTD-C9orf72 patients. Plans to report 12-month Dose 1 data and Dose 2 interim data by 2H 2025, seek regulatory feedback in 1H 2026. Completed PBFT02 manufacturing process development.

Passage Bio reported PBFT02's Phase 1/2 upliFT-D trial data for FTD-GRN, showing increased CSF PGRN and reduced plasma NfL levels. Dose 2, 50% lower, is being evaluated. Cash runway extended to 1Q 2027 via operational adjustments. 12-month Dose 1 data and Dose 2 interim data expected in 2H 2025.

Passage Bio reports interim data from the upliFT-D study showing PBFT02 increased CSF PGRN levels and reduced plasma NfL levels in FTD-GRN patients. Plans to evaluate a lower Dose 2, report 12-month data in 2H 2025, and seek regulatory feedback in 1H 2026. Extended cash runway to 1Q 2027 by reducing expenses and transitioning to outsourced analytical testing.

Passage Bio reports PBFT02's Phase 1/2 upliFT-D trial updates for FTD-GRN, showing increased CSF PGRN and reduced plasma NfL levels. Plans include Dose 2 evaluation, extending cash runway to 1Q 2027, and initiating FTD-C9orf72 dosing in 1H 2025. Manufacturing process scaled up for efficiency.

Lynx1 Capital Management Lp increased its stake in Passage Bio by purchasing 373,645 shares at $0.65 each, totaling $242,869.25, now owning 9,256,953 shares valued at ~$6,017,019.45. Institutional investors hold 53.48% of Passage Bio, with several analysts setting 'buy' ratings and price targets up to $13.00. Passage Bio develops gene therapies for CNS diseases.

Dose 1 of PBFT02 in upliFT-D trial for FTD-GRN achieved robust CSF progranulin levels, sustained up to 12 months, and was well-tolerated with revised immunosuppression. Updated data to be presented at ISFTD2024.

Dose 1 of PBFT02 in upliFT-D trial achieved robust CSF progranulin levels in FTD-GRN patients, sustained for up to 12 months, and was well-tolerated with no serious adverse events.

Passage Bio utilizza terapie geniche con virus adeno-associati per trattare la FTD, mirando a correggere i livelli carenti della proteina progranulina. La FTD richiede un trattamento che rallenti la progressione della malattia, e la partecipazione alla ricerca clinica è cruciale per il progresso. Il panorama della ricerca mostra progressi significativi nella comprensione della biologia della malattia, aumentando le possibilità di sviluppare trattamenti efficaci.